Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Cystitis cost-effectiveness of therapy

Introduction

Overview

Overview

Cystitis may present as a nonthreatening condition but can be a significant economic burden. According to an estimate the treatment of cystitis leads to a mean direct cost of 236 pounds per episode. Aetiology and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. Hyaluronan therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a Urinary tract infection.[1][2]

Cost-Effectiveness of Therapy

Cost-Effectiveness of Therapy

  • Hyaluronan is very cost effective in the long run when compared with all alternative treatments, despite initial high costs.[1]
  • Amoxicillin is almost two times cheaper than Aminoglycosides when used in the treatment of uncomplicated Cystitis.[2]
  • First and Second generation Cephalosporins are considered to be cost effective in treating lower urinary tract infections empirically.[3]
  • The use of Fluoroquinolone and nitrofurantoin is not cost effective.[4]
References

References

  1. ↑ 1.0 1.1 Riedl C, Engelhardt P, Schwarz B (2013). “Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines”. Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.
  2. ↑ 2.0 2.1 Ciani O, Grassi D, Tarricone R (2013). “An economic perspective on urinary tract infection: the “costs of resignation““. Clin Drug Investig. 33 (4): 255–61. doi:10.1007/s40261-013-0069-x. PMID 23475540.
  3. ↑ Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J (1998). “[Empirical treatment of urinary tract infections in the delivery room–findings and desires]”. Harefuah. 135 (9): 344–7, 408. PMID 10911441.
  4. ↑ Huang ES, Stafford RS (2002). “National patterns in the treatment of urinary tract infections in women by ambulatory care physicians”. Arch Intern Med. 162 (1): 41–7. PMID 11784218.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]